Pfizer hikes 2026 outlook despite flat Q3 revenue: names new CFO

What happened

Pfizer raised its full-year 2026 outlook after reporting better-than-expected Q3 2026 results, with $16.6B in revenue, down $71M from a year earlier but $700M above consensus. It named Cecile Guegan chief financial officer, effective November 1.

Confirmed

Global impact / market context

Pfizer's revenue mix is shifting: COVID product sales fell, with Comirnaty down $339M and Paxlovid down $771M, while Eliquis rose $513M and Padcev rose $255M. A new finance chief takes over as the company manages falling vaccine demand and relies on other drugs for growth.

Confirmed

Pfizer shares may be judged on whether newer growth drivers like Eliquis and Padcev can outweigh shrinking COVID revenue. The raised outlook signals management expects the business to hold up, but falling vaccination rates for Prevnar remain a drag on future sales.

Analyst inference

What to watch

1. Watch whether Comirnaty and Paxlovid sales keep falling, since they dropped 29% and 63% year over year and could reduce total revenue. Confirmed
2. Watch for details on the raised 2026 outlook, as a higher forecast may signal confidence in drug sales replacing lost COVID revenue. Proposed
3. Watch the CFO handover on November 1, because a new finance chief could shift spending priorities or how Pfizer guides investors. Analyst inference

Evidence

• seekingalpha.com